Given the extensive size and scope of the three independent studies on the potential use of Nu.Q® NETs in sepsis management, which included over 3000 patients and more than 14,000 patient samples, the webinar aims to provide stakeholders with a comprehensive understanding of the data and offer insights into how Volition's nucleosome quantification technology could be used in clinical practice. The webinar takes place on Monday, October 21, at 10:00 AM U.S. Eastern Time and will include updates from Volition ...

HENDERSON, Nev., Oct. 3, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, is hosting a symposium at ESICM Lives 2024 in Barcelona on October 7, 2024, during which experts from across the globe will present findings from large, independent studies regarding the potential of using Nu.Q® NETs to determine a 'treatable trait' to enhance sepsis management. The session, entitled 'NETs: Casting a new light on sepsis management', will take place at 12 ...

HENDERSON, Nev., Sept. 30, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has appointed Dr. Ethel Rubin to its board of directors, as an independent director, effective September 30, 2024. Dr. Rubin has also been appointed as a member of the Audit Committee and the Compensation Committee. Dr. Rubin has over 20 years' experience within the life sciences sector, leading healthcare innovation and commercialization strategies for a wide range of ...

Conference call to discuss financial and operational results scheduled for Thursday, August 15 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev., Aug. 14, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announced financial results and a business update for the second quarter of 2024. Volition management will host a conference call tomorrow, August 15 at 8:30 a.m. U.S. Eastern Time to discuss these results. Conference call details can be fo ...

Core Viewpoint - VolitionRx Limited has announced a stock offering that aims to raise approximately $7 million, with potential additional proceeds of up to $14.5 million through milestone-linked warrants, to support its research and development efforts in epigenetics and disease detection [1][4]. Group 1: Offering Details - The company is offering 12,727,273 shares of common stock at an offering price of $0.55 per share, along with milestone-linked warrants [1]. - The milestone-linked series A and B warrants have an exercise price of $0.57 per share and will expire under specific conditions related to significant agreements and FDA approvals [3]. - The offering is expected to close around August 12, 2024, pending customary closing conditions [1]. Group 2: Financial Implications - The gross proceeds from the offering are expected to be approximately $7 million before deducting fees and expenses [4]. - If fully exercised, the milestone-linked warrants could provide an additional $14.5 million in gross proceeds [4]. Group 3: Company Overview - Volition is a multi-national company focused on advancing epigenetics to improve disease detection and monitoring [7]. - The company is developing cost-effective blood tests for diagnosing and monitoring various diseases, including certain cancers and conditions associated with NETosis [8]. - Research and development activities are primarily based in Belgium, with additional offices in the U.S., Nevada, London, and Singapore [9].

PharmaVentures has been engaged to act as an advisor to Volition to help secure licensing deals with industry leaders for both Nu.Q® Cancer – a range of simple blood-based assays to help detect, guide treatment, and monitor cancer, and Capture-PCR™ – a novel detection method for liquid biopsy in cancer and potentially other diseases. Adrian Dawkes, Managing Director, PharmaVentures, said: Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving li ...

VolitionRx Limited (NYSE:VNRX) Q1 2024 Results Conference Call May 14, 2024 8:30 AM ET Company Participants Cameron Reynolds - President, CEO Terig Hughes - CFO Andrew Retter - CMO Gael Forterre - CCO Louise Batchelor - Chief Marketing & Communications Officer Conference Call Participants Bruce Jackson - Benchmark Company Tim Moore - EF Hutton Ilya Zubkov - Freedom Broker Steven Ralston - Zacks Richard Deutsch - Sutter Securities Operator Good morning, ladies and gentlemen, and thank you for standing by. We ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36833 VolitionRx Limited (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization ...

FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 13, 2024 VolitionRx Limited (Exact name of registrant as specified in its charter) | Delaware | 001-36833 | 91-1949078 | | --- | --- | --- | | (State or other jurisdiction | (Commission | (IRS Employer | | of Incorporation) | File Number) | Identification Number) | 1489 West Warm Springs Road, Suite 110 Henderson, Nevada 89014 (Address of Principal Executive Of ...

Financial Data and Key Metrics Changes - The company recorded revenue of $244,000 for Q4 2023, a 104% increase year-over-year [27] - Full-year revenue for 2023 was $775,000, reflecting a 153% increase compared to the previous year [28] - The net loss for Q4 2023 was $8.8 million, compared to $7.3 million for Q4 2022, with a full-year net loss of $35.7 million, up from $30.6 million in 2022 [30] Business Line Data and Key Metrics Changes - Revenue from the Nu.Q Vet cancer test for 2023 was $475,000, a 194% increase year-over-year, primarily due to sales through IDEXX [28] - Nu.Q Discover generated $300,000 in revenue for 2023, representing a 107% growth over 2022 [28] - The company supplied kits for over 58,000 tests in 2023, five times the number from the previous year [31] Market Data and Key Metrics Changes - The Nu.Q Vet cancer test is now available in multiple countries, including the U.S., U.K., Ireland, Portugal, Singapore, Taiwan, and Italy [42] - The company has signed a supply agreement with Fujifilm Vet Systems for the Nu.Q Vet Cancer Test in Japan, indicating significant market expansion [33][54] Company Strategy and Development Direction - The company aims to achieve cash positivity from existing milestone payments and expected revenue growth as more partners launch the Nu.Q Vet test [67] - There is a focus on non-dilutive funding strategies to support the Nu.Q NET pillar, targeting $25 million [68] - The company is exploring licensing opportunities for its CTCF and Nu.Q cancer technologies, anticipating ongoing royalties and milestone payments [69] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about revenue acceleration in 2024 as additional distributors come online with the Nu.Q Vet cancer test [28] - The company is confident in the potential of the Nu.Q NET and Capture-PCR technologies, with expectations for significant data publication and commercial discussions in the coming months [49][63] - Management highlighted the importance of education for veterinarians to incorporate the Nu.Q test into routine wellness visits [52] Other Important Information - The company ended 2023 with cash and cash equivalents of approximately $20.7 million, up from $10.9 million at the end of 2022 [29] - The company received $13 million in milestone payments from Heska Corporation in December 2023 [41] Q&A Session Summary Question: What is the status of IDEXX's marketing launch? - Management confirmed that IDEXX has completed preparations for the marketing launch and that the revenue from the kits is approximately $10 per kit [71][73] Question: What is the timeline for achieving revenues on the sepsis side? - Management indicated that significant data will be generated throughout the year, with expectations for revenues from the Nu.Q NET test within the next 12 months [89][91] Question: What types of cancer are most promising for detection with Capture-PCR? - Management noted that transcription factors are indicative of all types of cancer, with initial focus on prevalent cancers like lung and colorectal [92] Question: Will there be interim analyses available for the 500-patient study? - Management stated that while the full study won't be finished this year, there may be interim analyses available for presentation at upcoming conferences [108] Question: What is the expected profitability between Discover and Vet? - Management indicated that both segments are highly profitable, with Vet expected to be more profitable once scaled [113]